Annals of Oncology 12:S95-S99, 2001
© 2001 European Society for Medical Oncology
Reviews |
Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours
Department of Internal Medicine and Gastroenterology, University of Bologna Bologna, Italy
Correspondence to: Paola Tomassetti, MD Department of Internal Medicine and Gastroenterology S. Orsola Hospital Via Massarenti 9 40138 Bologna Italy E-mail: tomasset{at}med.unibo.it
Gastroenteropancreatic (GEP) neoplasms originate from any of the various cell types belonging to the neuroendocrine system. A general characteristic of GEP endocrine tumours is that the vast majority produce and secrete a multitude of peptide hormones and amines. Many patients with malignant metastasising tumours present clinical symptoms related to hormone hyperproduction. These include the so-called carcinoid syndrome, characterised by flushing, diarrhoea, wheezing and right heart disease, which is predominantly associated with the serotonin-and tachykinins-producing carcinoids of the midgut. Several types of syndrome associated with GEP endocrine tumors are caused by overproduction of a specific hormone. For instance, the well-known Zollinger-Ellison syndrome is gastrin-mediated. The so-called ‘insulinoma syndrome’ depends on excessive production of insulin and proinsulin, resulting in hypoglycemia. The ‘glucagonoma syndrome’ is characterised by necrolytic migratory erythema, diabetes and diarrhoea. The Verner-Morrison syndrome, which is brought about by high circulating levels of vasointestinal peptide (VIP), produces severe secretory diarrhoea. Finally the ‘somatostatinoma syndrome’ involves gallbladder dysfunction and gall stones, diarrhoea with or without steatorrhea, and impaired glucose tolerance.
The biochemical diagnosis of endocrine digestive tumors is based on general and specific markers. The best general markers are chromogranin A (CgA) and pancreatic polypeptide (PP). Specific markers for endocrine tumors include insulin, gastrin, glucagon , vaso intestinal polypeptide (VIP), somatostatin and the primary cathabolic product of serotonin, 5-hydroxyndoleacetic acid (5-HIAA). Localisation procedures commonly applied, in the diagnosis of endocrine tumours include ultrasound (US), computed tomography (Cl and somatostatin receptor scintigraphy (SRS).
carcinoid, chromogranin A, gastrinoma, neuroendocrine tumor, octreoscan scintigraphy, somatostatin receptors, Zollinger-Ellison syndrome
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. R Halfdanarson, J. Rubin, M. B Farnell, C. S Grant, and G. M Petersen Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors Endocr. Relat. Cancer, June 1, 2008; 15(2): 409 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Vilar, R. Salazar, J. Perez-Garcia, J. Cortes, K. Oberg, and J. Tabernero Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors Endocr. Relat. Cancer, June 1, 2007; 14(2): 221 - 232. [Abstract] [Full Text] [PDF]
|
|